by The survival rates of prostate cancer are lower than in 2010, as a study showed.
The proportion of men who live on for a decade after the disease has been diagnosed has increased after the previous 40 years.
The 10-year survival rate rose from 21.7 percent in 1971-72 to 79.7 percent in 2010-11.
According to the analysis of the London School of Hygiene and Tropical Medicine (LSHTM), it has since dropped slightly to 78.9 percent.
It reached the climax in 2015-16 with 79.8 percent, based on the data that the researchers viewed.
The study financed by Cancer Research UK examined more than 10.8 million cancer patients in England and Wales over more than 50 years.
It found that progress had slowed down in the Great Britain across the board, with the difference between the most fatal types of the disease wider than ever.
For example, the 10-year survival rate for testicular cancer was 97 percent, compared to 4.3 percent in the case of pancreatic cancer in 2018.
According to Cancer Research UK, screening programs in the chest, intestine and cervix improved the survival rates for cancer, but others have been left behind.
The survival for other types such as stomach, lung and brain cancer has increased only a small amount in the past 50 years.
The Telegraph is committed to a prostate crab screening program, which gives the strongest of the disease that belongs over 50 years, black men and those with a history of the family.
Prostate is the most common cancer in Great Britain. 55,000 men diagnosed every year.
The risk of over-treatment was one of the most important arguments against a screening program.
Prostate Cancer UK said that “outdated” NHS guidelines disabled the introduction of a screening program and prompted 5,000 men to be treated unnecessarily for cancer every year, which should only be monitored because they would probably not deteriorate during their lives.
The British National Screening Committee currently evaluates whether a program for prostate cancer should be introduced.
The government also started a call for evidence to form a national cancer plan in February that will revise and improve treatment.
Michelle Mitchell, Managing Director of Cancer Research UK, said that the plan must “include obligations for the earlier knowledge of earlier types of cancer and the support of new treatments so that each patient can hope for further moments with the people they love”.
Michel Coleman, professor of epidemiology and statistics at LSHTM, said: “Since I started my career in cancer research, I have recorded considerable increase in survival for most types of cancer.
“Our understanding of cancer biology has expanded, effective screening programs have been introduced and new treatments have been developed. If this trend has devastating consequences.”
Cancer Research UK calls for the national cancer plan to reduce waiting times for diagnosis and treatment, and explains that some patients are exposed to unacceptable delays.
The plan should also improve the early diagnosis of cancer in order to increase participation in existing screening programs, and the commitment to the complete introduction of lung cancer screening in England until 2029.
The study was published in the Lancet Regional Health Europe Journal.
A spokesman for the Ministry of Health said: “We prioritize cancer care because we turn over more than a decade of neglecting our NHS.
“We are already seeing progress, and between July 2024 and May 2025, 95,000 people diagnosed or excluded cancer compared to the same period last year.
“The national cancer plan will determine how we will further improve the survival rates and address the variation between different types of cancer.”
An NHS spokesman said: “The data in this study comes from seven years, and now the NHS diagnoses more men with prostate cancer early than ever. So if you need treatment, this has the best chance of success.
“We also use Hi-Tech MPMRI scans to improve the diagnosis of prostate cancer and to set innovative treatments such as personalized vaccines to improve cancer patients.”
